Palladio Biosciences

Palladio bags $20 million Series B to topple a problematic kidney disease drug
Endpoints
Fri, 09/25/20 - 10:33 am
Palladio Biosciences
autosomal dominant polycystic kidney disease
kidney disease
lixivaptan
Otsuka
Samsca